BenQ Medical Technology (4116) — Capital Reinvestment Ratio
Latest as of June 2025:
0.08x
BenQ Medical Technology (4116) has a Capital Reinvestment Ratio of 0.08x as of June 2025, meaning it reinvests 0% of its operating cash flow (NT$179.07 Million) in capital expenditures (NT$14.79 Million). See 4116 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.08x
Capex / Operating Cash Flow
Operating Cash Flow
NT$179.07 Million
TWD
Capital Expenditures
NT$14.79 Million
TWD
Data as of
Jun 2025
Most recent filing
BenQ Medical Technology Capital Reinvestment Ratio (2017–2024)
This chart tracks BenQ Medical Technology's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for BenQ Medical Technology (2017–2024)
Year-by-year Capital Reinvestment Ratio for BenQ Medical Technology from 2017 to 2024. For live market cap and broader valuation context, see 4116 market cap overview.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.79x | NT$222.22 Million | NT$175.48 Million | ▲ +150.8% |
| 2023 | 0.31x | NT$442.35 Million | NT$139.28 Million | ▲ +98.6% |
| 2022 | 0.16x | NT$378.77 Million | NT$60.05 Million | ▼ -41.6% |
| 2021 | 0.27x | NT$121.35 Million | NT$32.92 Million | ▼ -3.0% |
| 2020 | 0.28x | NT$151.48 Million | NT$42.37 Million | ▲ +123.8% |
| 2019 | 0.12x | NT$169.23 Million | NT$21.15 Million | ▼ -49.8% |
| 2018 | 0.25x | NT$126.10 Million | NT$31.36 Million | ▼ -83.8% |
| 2017 | 1.54x | NT$72.97 Million | NT$112.31 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow